[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 19,240
Citations 0
Editor's Note
September 27, 2019

Lefamulin—A New Antibiotic for Community-Acquired Pneumonia

Author Affiliations
  • 1Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor
  • 2Associate Editor, JAMA
JAMA. 2019;322(17):1671-1672. doi:10.1001/jama.2019.16215

A robust antibiotic pipeline is essential for patient care and public health. Yet compared with other classes of drugs, the development of antibiotics presents unique scientific, regulatory, and economic challenges. Most notably, antibiotics provide less financial reward for pharmaceutical companies because these medications are used for a short duration and newer agents are often restricted for use only in the setting of antimicrobial resistance. In fact, most large pharmaceutical companies have reduced or stopped antibiotic research altogether, leaving the critical task of discovering new antibiotics to small companies with limited budgets and research capacity. For these and other reasons, the development and approval of a new antibiotic is a rare occurrence and a reason to celebrate.